Effects of Three Thiazolidinediones on Metabolic Regulation and Cold-Induced Thermogenesis

Area of Science:

• Metabolic diseases
• Pharmacology
• Adipose tissue biology

Background:

• Insulin resistance is linked to metabolic disorders like type 2 diabetes and hypertension.
• Thiazolidinediones (TZDs) activate peroxisome proliferator-activated receptor gamma (PPARγ) to combat insulin resistance.
• Existing research lacks direct comparisons of TZD metabolic effects.

Purpose of the Study:

• To compare the metabolic and thermogenic effects of lobeglitazone (Lobe), rosiglitazone (Rosi), and pioglitazone (Pio).
• To evaluate TZD efficacy in adipocytes, macrophages, and animal models of obesity and diabetes.

Main Methods:

• In vitro studies on adipocytes and macrophages exposed to pro-inflammatory stimuli.
• In vivo studies using obese diabetic db/db mice and lean mice.
• Analysis of adipogenesis, glucose uptake, inflammatory gene expression, and thermogenic markers.

Main Results:

• Lobeglitazone (Lobe) demonstrated superior stimulation of adipogenesis and insulin-dependent glucose uptake in adipocytes compared to Rosi and Pio.
• Lobe effectively suppressed pro-inflammatory gene expression in macrophages and adipocytes.
• In db/db mice, Lobe improved glucose intolerance by enhancing insulin sensitivity and reducing inflammation in white adipose tissue.
• Lobe promoted beige adipocyte formation and thermogenic gene expression in lean mice more effectively than Rosi and Pio.

Conclusions:

• Lobeglitazone (Lobe) exhibits enhanced efficacy in ameliorating insulin resistance and boosting thermogenesis at lower concentrations compared to Rosi and Pio.
• These findings highlight Lobe's potential as a superior therapeutic agent for metabolic disorders.